Adaptive Biotechnologies is a biotechnology company that develops and commercializes immune-driven medicine. The company's proprietary immune profiling platform generates data-driven insights to help researchers and clinicians better understand the immune system and develop new diagnostics, therapies, and vaccines for a wide range of diseases. Adaptive's technology is based on high-throughput sequencing of T-cell and B-cell receptors, which allows for the identification of disease-specific biomarkers and the development of personalized treatments. The company has partnerships with leading pharmaceutical companies and academic institutions, and has received funding from investors such as Viking Global Investors and Matrix Capital Management.